ArticleOncology letters2026
BUD23 is associated with malignancy and correlates with immune infiltration in NSCLC.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the primary cause of cancer-related mortality worldwide. BUD23, also known as Williams-Beuren syndrome critical region 22, is an rRNA methyltransferase involved in ribosome maturation and RNA methylation. It has been reported to promote tumor progression in several malignancies. Although BUD23 has been implicated in drug resistance in lung cancer cells, its role in non-small cell lung cancer (NSCLC) remains incompletely understood. In the present study, transcriptomic and proteomic datasets were analyzed to evaluate the expression of BUD23 in NSCLC and normal tissues, and Kaplan-Meier survival analysis was performed to assess its prognostic significance. Immune infiltration algorithms were used to examine the correlation between BUD23 expression and tumor immune cell infiltration in NSCLC. Gene set enrichment analysis (GSEA), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and single-cell enrichment analysis were conducted to explore the biological pathways associated with BUD23 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.